Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?

Affiliations

¹ Swiss Cardiovascular Center, University of Bern, Switzerland (F.H.M.).
² Department of Cardiology, Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI (C.B.).
³ NYU Langone Hospitals, New York University School of Medicine (S.B.).

Comment

Franz H Messerli et al. Circulation. 2022.

. 2022 Feb 8;145(6):413-415.

doi: 10.1161/CIRCULATIONAHA.121.057835. Epub 2022 Feb 7.

¹ Swiss Cardiovascular Center, University of Bern, Switzerland (F.H.M.).
² Department of Cardiology, Lifespan Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, RI (C.B.).
³ NYU Langone Hospitals, New York University School of Medicine (S.B.).

No abstract available

Keywords: angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; myocardial infarction; randomized controlled trial.

Comment on

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.
Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC, Ryan PB, Hripcsak G. Chen R, et al. Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26. Hypertension. 2021. PMID: 34304580 Free PMC article.